DURECT Corporation - Drug delivery technologies treating chronic debilitating disease

Board of Directors

Corporate Policies/Governance

Driving Directions

Development Pipeline

Commercial Products

Research Programs

Business Development Approach

The SABER® and Cloud™ Injectable Depot Systems

ORADUR® Oral Delivery System

TRANSDUR® Transdermal Technology System

Localized Drug Delivery

Stock Information

Corporate Presentation

Earnings Estimate

Analyst Coverage

Financial Reports

Information Request

Benefits Overview

Attention Recruiters

About DURECT

Products

Business Development

Science & Technologies

Investor Relations

Careers

News

DURECT: Developing products to treat chronic debilitating disease and technologies that enable biotechnology products.

DURECT Featured Clinical Products

Latest News

TRANSDUR®-Sufentanil

Indication:

Focus:

Chronic Pain

TRANSDUR® Sufentanil
A proprietary transdermal delivery system utilizing sufentanil, a potent opioid, for the treatment of chronic pain.

Learn more
View complete product pipeline

May 10, 2013
DURECT Announces Update on Remoxy®

May 02, 2013
DURECT Corporation Announces First Quarter 2013 Financial Results and Update of Programs

April 16, 2013
DURECT Announces Submission of New Drug Application for POSIDUR™ (SABER®-Bupivacaine)

February 28, 2013
DURECT Corporation Announces Fourth Quarter 2012 Financial Results and Update of Programs

2012 Letter to the Shareholders

2012 Letter to the Shareholders

© 2000-2013 DURECT Corporation

Last updated: September 20, 2012
built@zoomedia.com

Contact